

# Raymond L Benza

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2216146/raymond-l-benza-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179  
papers

12,332  
citations

50  
h-index

109  
g-index

234  
ext. papers

14,516  
ext. citations

3.9  
avg, IF

5.85  
L-index

#	Paper	IF	Citations
179	Application of the REVEAL risk score calculator 2.0 in the CHEST study.. <i>Respiratory Medicine</i> , <b>2022</b> , 195, 106783	4.6	
178	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. <i>International Journal of Cardiology Congenital Heart Disease</i> , <b>2022</b> , 8, 100354	0.7	
177	Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 172-182	5.8	2
176	The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study. <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e25397	2	1
175	Assessing hemodynamic response to submaximal exercise in pulmonary arterial hypertension patients using an implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 430-434	5.8	0
174	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14,	7.6	1
173	Application of the REVEAL risk score calculator 2.0 in the PATENT study. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 189-192	3.2	2
172	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 613-622	4.7	4
171	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2021</b> , 159, 337-346	5.3	29
170	PPAR $\gamma$ increases HUWE1 to attenuate NF- $\kappa$ B/p65 and sickle cell disease with pulmonary hypertension. <i>Blood Advances</i> , <b>2021</b> , 5, 399-413	7.8	2
169	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2021</b> , 17, 134-144	2.1	
168	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	2
167	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	9
166	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 945-953	5.8	4
165	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 300-309	5.8	19
164	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 1407-1415	10.2	7
163	Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. <i>Chest</i> , <b>2020</b> , 157, 162-172	5.3	17

162	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020964342	2.7	1
161	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020973124	2.7	2
160	Sex-Based Differences in Left Ventricular Assist Device Utilization: Insights From the Nationwide Inpatient Sample 2004 to 2016. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006082	7.6	19
159	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005095	5.8	5
158	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894019851696	2.7	5
157	Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 556-563	16.2	28
156	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Chest</i> , <b>2019</b> , 156, 53-63	5.3	22
155	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , <b>2019</b> , 21, 45	4.7	10
154	Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. <i>Chest</i> , <b>2019</b> , 156, 323-337	5.7	201
153	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	32
152	Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2019</b> , 291, 134-139	3.2	26
151	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. <i>Chest</i> , <b>2019</b> , 156, 1176-1186	5.3	13
150	Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. <i>Annals of Thoracic Surgery</i> , <b>2019</b> , 108, 1178-1182	2.7	4
149	Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. <i>ASAIO Journal</i> , <b>2019</b> , 65, 436-441	3.6	3
148	Integrated use of cardiac MRI and the CardioMEMS <sup>®</sup> HF system in PAH: the utility of coincident pressure and volume in RV failure-the NHLBI-VITA trial. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2019</b> , 9, 492-501	2.6	2
147	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238	35.1	55
146	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 43-50	5.8	16
145	Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 227-230	5.8	2

144	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	75
143	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019837849	2.7	1
142	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 836-843	5.8	14
141	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. <i>Chest</i> , <b>2018</b> , 154, 126-135	5.3	23
140	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 166-174	10.2	14
139	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. <i>International Journal of Cardiology</i> , <b>2018</b> , 254, 299-301	3.2	8
138	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 948-955	5.8	7
137	Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217741480	2.7	7
136	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 365-375	5.8	27
135	Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018794051	2.7	9
134	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 771-779	7.9	24
133	A Novel Compound, "FA-1" Isolated from <i>Prunus mume</i> , Protects Human Bronchial Epithelial Cells and Keratinocytes from Cigarette Smoke Extract-Induced Damage. <i>Scientific Reports</i> , <b>2018</b> , 8, 11504	4.9	10
132	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. <i>Advances in Pulmonary Hypertension</i> , <b>2018</b> , 16, 125-135	0.5	6
131	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 513-519	5.8	22
130	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 696-705	5.8	16
129	Response. <i>Chest</i> , <b>2018</b> , 154, 1262-1264	5.3	
128	Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004757	5.8	11
127	Significance of Residual Mitral Regurgitation After Continuous Flow Left Ventricular Assist Device Implantation. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 81-88	7.9	50

126	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1661-1670	10.2	38
125	Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. <i>ASAIO Journal</i> , <b>2017</b> , 63, 251-256	3.6	12
124	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S28-S34	4.6	6
123	Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 539-542	2.7	7
122	In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy. <i>Human Gene Therapy</i> , <b>2017</b> , 28, 681-689	4.8	3
121	MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 522-530	2.7	13
120	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S18-S22	4.6	13
119	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 606-618	3.9	5
118	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. <i>ClinicoEconomics and Outcomes Research</i> , <b>2017</b> , 9, 731-739	1.7	13
117	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	74
116	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 741-746	2.7	10
115	Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI <b>2017</b> , 2017,		5
114	TLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling. <i>Frontiers in Bioscience - Landmark</i> , <b>2016</b> , 21, 397-409	2.8	13
113	Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension: longitudinal insights from an implantable hemodynamic monitor. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 616-618	2.7	6
112	In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 551-556	2.7	5
111	Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 586-596	2.7	13
110	Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, 208-18	10.2	68
109	Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 269-73	4.7	8

108	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 362-8	5.8	74
107	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 438-47	5.8	21
106	Successful treatment of acute left ventricular assist device thrombosis and cardiogenic shock with intraventricular thrombolysis and a tandem heart. <i>ASAIO Journal</i> , <b>2015</b> , 61, 98-101	3.6	5
105	Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 152-64	13.6	62
104	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1345-54	10.2	60
103	Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 329-37	5.8	47
102	A new Bayesian network-based risk stratification model for prediction of short-term and long-term LVAD mortality. <i>ASAIO Journal</i> , <b>2015</b> , 61, 313-23	3.6	32
101	Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary observations from a high-volume transplant centre. <i>ESC Heart Failure</i> , <b>2015</b> , 2, 150-159	3.7	13
100	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. <i>Current Opinion in Organ Transplantation</i> , <b>2015</b> , 20, 570-6	2.5	6
99	Five-Year outcomes of patients enrolled in the REVEAL Registry. <i>Chest</i> , <b>2015</b> , 148, 1043-54	5.3	263
98	Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 356-61	5.8	80
97	Spontaneous microbubbles in the aortic root and thrombosis of a continuous-flow left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 550-1	5.8	2
96	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 521-7	5.8	28
95	Management of pulmonary hypertension due to heart failure with preserved ejection fraction. <i>Current Hypertension Reports</i> , <b>2014</b> , 16, 501	4.7	3
94	Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 415-21	3.8	3
93	Imatinib in pulmonary arterial hypertension: c-Kit inhibition. <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 452-5	2.7	29
92	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. <i>Chest</i> , <b>2014</b> , 146, 1494-1504	5.3	94
91	Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 485-91	3.3	8

90	Ambulatory Hemodynamic Monitoring in the Management of Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , <b>2014</b> , 13, 81-85	0.5	2
89	One-year experience with intravenous treprostinil for pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2013</b> , 32, 889-96	5.8	27
88	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2013</b> , 32, 1179-86	5.8	33
87	Pulmonary arterial hypertension: epidemiology and registries. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D51-9	15.1	338
86	Harvest of pulmonary artery endothelial cells from patients undergoing right heart catheterization. <i>Journal of Heart and Lung Transplantation</i> , <b>2013</b> , 32, 746-9	5.8	12
85	Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 38-44	3.3	26
84	Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 116-20	2.7	8
83	Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. <i>Chest</i> , <b>2013</b> , 144, 1521-1529	5.3	58
82	Salvage peripheral extracorporeal membrane oxygenation using Cobe Revolution(®) centrifugal pump as a bridge to decision for acute refractory cardiogenic shock. <i>Journal of Cardiac Surgery</i> , <b>2012</b> , 27, 521-7	1.3	12
81	An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. <i>Chest</i> , <b>2012</b> , 142, 448-456	5.3	726
80	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 913-33	5.8	165
79	Pulmonary hypertension. <i>Heart Failure Clinics</i> , <b>2012</b> , 8, xxi-xxii	3.3	2
78	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. <i>Gastroenterology Insights</i> , <b>2012</b> , 4, 2	2.1	2
77	Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1049-60	7	11
76	Late gadolinium enhancement in pulmonary hypertension predicts clinical events. <i>Journal of Cardiovascular Magnetic Resonance</i> , <b>2012</b> , 14,	6.9	78
75	The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. <i>Chest</i> , <b>2012</b> , 141, 354-362	5.3	329
74	Pulmonary hypertension: chapters of innovation and tribulation. <i>European Heart Journal</i> , <b>2012</b> , 33, 961-89.5		6
73	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. <i>Gastroenterology Insights</i> , <b>2012</b> , 4, e2	2.1	

72	The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists. <i>Transplantation</i> , <b>2012</b> , 94, 885-93	1.8	19
71	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 982-9	5.8	61
70	The role of fibrinolytic genes and proteins in the development of allograft vascular disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 935-44	5.8	2
69	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 1327-33	5.8	69
68	Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 1053-61	15.1	48
67	The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. <i>Chest</i> , <b>2011</b> , 139, 128-37	5.3	231
66	Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine trafficking. <i>Human Gene Therapy</i> , <b>2011</b> , 22, 293-301	4.8	17
65	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 426-35	4.5	99
64	Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). <i>Circulation</i> , <b>2010</b> , 122, 164-72	16.7	1079
63	Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. <i>Chest</i> , <b>2010</b> , 137, 376-87	5.3	798
62	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1915-22	15.1	381
61	Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. <i>Transplantation</i> , <b>2010</b> , 90, 298-305	1.8	53
60	Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 835-42	10.2	170
59	Safety and efficacy of ibutilide in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , <b>2009</b> , 28, 505-7	5.8	0
58	Transforming growth factor-beta polymorphisms and cardiac allograft rejection. <i>Journal of Heart and Lung Transplantation</i> , <b>2009</b> , 28, 1057-62	5.8	11
57	Future perspectives for the treatment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S108-S117	15.1	50
56	Interventional and surgical modalities of treatment in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S67-S77	15.1	191
55	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , <b>2009</b> , 14, 156-60	2.6	7



54	Serotonin transporter polymorphisms in patients with portopulmonary hypertension. <i>Chest</i> , <b>2009</b> , 135, 1470-1475	5.3	34
53	Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1683-92	15.1	142
52	Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , <b>2008</b> , 27, 610-5	5.8	17
51	Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2008</b> , 27, 780-8	5.8	30
50	Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. <i>Chest</i> , <b>2008</b> , 134, 139-45	5.3	51
49	Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. <i>Chest</i> , <b>2008</b> , 134, 775-782	5.3	82
48	Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. <i>Lung</i> , <b>2008</b> , 186, 247-254	2.9	20
47	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , <b>2008</b> , 48, 196-203	11.2	189
46	Genetic testing in cardiovascular disease. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 727-37	15.1	51
45	Post-heart transplant diastolic dysfunction is a risk factor for mortality. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1064-9	15.1	40
44	Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. <i>Chest</i> , <b>2007</b> , 132, 37-43	5.3	33
43	REVEAL REGISTRY: BASELINE CHARACTERISTICS OF THE FIRST 1,226 ENROLLED PATIENTS. <i>Chest</i> , <b>2007</b> , 132, 473B	5.3	2
42	Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 63-9	5.8	49
41	Management of pulmonary arterial hypertension with a focus on combination therapies. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 437-46	5.8	59
40	Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 494-7	5.8	7
39	Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 584-92	5.8	93
38	Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 732-8	5.8	34
37	Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. <i>Chest</i> , <b>2006</b> , 129, 1009-15	5.3	44

36	Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. <i>Chest</i> , <b>2006</b> , 129, 683-8	5.3	242
35	Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension. <i>Echocardiography</i> , <b>2006</b> , 23, 872-9	1.5	16
34	Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. <i>Journal of Heart and Lung Transplantation</i> , <b>2005</b> , 24, 2196-201	5.8	84
33	Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 172, 1586-9	10.2	183
32	Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 1963-71	27.4	511
31	Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 1973-81	15.1	74
30	The impact of arrhythmias in acute heart failure. <i>Journal of Cardiac Failure</i> , <b>2004</b> , 10, 279-84	3.3	51
29	Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation. <i>American Journal of Transplantation</i> , <b>2003</b> , 3, 484-91	8.7	11
28	Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 997-1003	15.1	401
27	Infection in ventricular assist devices: prevention and treatment. <i>Annals of Thoracic Surgery</i> , <b>2003</b> , 75, S48-57	2.7	112
26	Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 515-8	5.8	10
25	Therapeutic angiogenesis: review of current concepts and future directions. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 370-82	5.8	16
24	Commentary: non-immunologic vascular failure of the transplanted heart. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 241-3	5.8	2
23	Transmyocardial and percutaneous myocardial revascularization: current concepts and future directions. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 837-42	5.8	0
22	The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. <i>Circulation</i> , <b>2003</b> , 107, 1359-65	16.7	869
21	Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 1541-7	27.4	848
20	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 970-5	15.1	196
19	Treatment of end-stage heart disease with outpatient ventricular assist devices. <i>Annals of Thoracic Surgery</i> , <b>2002</b> , 73, 1489-93; discussion 1493-4	2.7	23

18	Cardiac transplant patients response to the (31)P MRS stress test. <i>Journal of Heart and Lung Transplantation</i> , <b>2002</b> , 21, 522-9	5.8	20
17	Aortic graft transplantation in mice. <i>Journal of Heart and Lung Transplantation</i> , <b>2002</b> , 21, 1319-21	5.8	5
16	Polyphenolics Increase t-PA and u-PA Gene Transcription in Cultured Human Endothelial Cells. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 155-162	3.7	62
15	Ethanol-Induced Up-Regulation of the Urokinase Receptor In Cultured Human Endothelial Cells. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 163-170	3.7	15
14	Identification of a 251-bp Fragment of the PAI-1 Gene Promoter That Mediates the Ethanol-Induced Suppression of PAI-1 Expression. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 629-636	3.7	15
13	Cardiomyopathy in a carrier of Duchenne's muscular dystrophy. <i>Journal of Heart and Lung Transplantation</i> , <b>2001</b> , 20, 781-4	5.8	33
12	Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1675-81	9.4	6
11	Ethanol-Induced Up-Regulation of Candidate Plasminogen Receptor Annexin II in Cultured Human Endothelial Cells <b>2000</b> , 24, 754		5
10	Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 1504-1509	7	17
9	Infection during circulatory support with ventricular assist devices. <i>Annals of Thoracic Surgery</i> , <b>1999</b> , 68, 711-6	2.7	74
8	Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 5, 113-118	5.1	3
7	Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 5, 143-150	5.1	14
6	Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1998</b> , 18, 1803-9	9.4	26
5	Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. <i>Circulation</i> , <b>1998</b> , 98, 2248-54	16.7	46
4	Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. <i>Chest</i> , <b>1998</b> , 114, 334-6	5.3	21
3	Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 3215-23	9.4	47
2	Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. <i>Biochemistry</i> , <b>1996</b> , 35, 6080-8	3.2	20
1	Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1995</b> , 15, 410-9	9.4	24

